Finn
TMO Life Science Tools · Large cap · Healthcare · Diagnostics · Thesis updated October 25, 2026

A science giant finding growth in services and AI

01 Running thesis

Execution meets a stabilizing market

Thermo Fisher is a high-quality science supplier, and its near-term story is improving. The company delivered a strong beat in the third quarter of 2026 with 6 percent organic growth and 15 percent adjusted earnings growth. That supports the bull case that a scaled operator can capitalize on a stabilizing macro environment.

The strongest end market is pharma and biotech, which grew in the high single digits. This was led by Pharma Services and new offerings like agentic artificial intelligence for clinical research. China also rebounded to low double-digit growth, answering a major lingering question for investors.

The bear case centers on specific soft spots and the sustainability of recent beats. Management kept 2026 full-year organic growth guidance at roughly 4 percent, cautioning that some third-quarter strength in Pharma Services was pulled forward from the fourth quarter.

Meanwhile, academic and government spending remains flat globally. A true acceleration in the underlying business requires these budget-sensitive customers to return to consistent growth.

Oct 2026▲Thermo Fisher reported a strong third quarter with 6 percent organic revenue growth. China accelerated to low double-digit growth, easing prior regional concerns.
Jul 2026▲The Q2 2026 Form 10-Q formalized the broad-based strengthening of customer activity and the 5 percent organic revenue beat.
Jul 2026▲Thermo Fisher reported a strong Q2 2026 with 5 percent organic growth. Management raised the full-year organic growth outlook to about 4 percent, citing broad improvement across end markets.
May 2026→The Q1 2026 Form 10-Q confirmed the earnings call story. Pharma and biotech stayed strong, while academic and government demand remained soft in the U.S. and China.
Apr 2026▲Thermo Fisher reported Q1 2026 revenue of $11.01 billion and adjusted EPS of $5.44. Management raised full-year revenue and adjusted EPS guidance, helped by Clario and the first-quarter beat.
Feb 2026→The 2025 Form 10-K confirmed the existing business trends. The main update was sharper risk language around cyber attacks and competition for skilled talent.
Jan 2026▲Q4 2025 showed stronger pharma and biotech demand. The first 2026 outlook called for 3 percent to 4 percent organic growth and 6 percent to 8 percent adjusted EPS growth.
Oct 2025→The Q3 2025 filing showed Analytical Instruments returning to positive organic growth. It also confirmed ongoing weakness in academic and government demand and pressure in China.
02 Business model

Tools, services, and scale

Thermo Fisher makes money by selling what labs and healthcare groups need to do science. That includes consumables, instruments, diagnostics, software, clinical trial services, and biopharma manufacturing support. Many customers buy again and again because labs need steady supplies and trusted workflows.

Scale is the moat. Thermo Fisher has a broad catalog, deep customer ties, and a large sales force. A drug company can use it for research tools, trial support, testing, and manufacturing services. That makes Thermo Fisher hard to replace.

The model can still slow when customers delay purchases. Instruments are big-ticket items, so academic labs, government labs, and industrial customers can pause spending when budgets are tight. China is also a key swing factor because weak local demand can hit several parts of the business at once.

Mergers and internal development are part of the playbook. The recent push into AI-based clinical research assistants and the Clario integration add new layers of growth, though they also require careful execution and capital.

03 Product portfolio

What it sells

Cash cow

Laboratory Products and Biopharma Services

This is the largest segment by revenue. It includes lab products, research and safety channels, pharma services, and clinical research.

Growth engine

Life Sciences Solutions

This unit sells reagents, instruments, and consumables used in biological research and drug production. BioProduction remains a key driver here.

Steady

Analytical Instruments

This segment includes tools such as electron microscopes, chromatography systems, and mass spectrometers.

Steady

Specialty Diagnostics

This unit sells diagnostic tests and related products to healthcare and research customers.

Option

Clinical research and AI services

The company is deploying agentic AI to create clinical research assistants, enhancing its trial support offerings.

04 Business segments

Largest piece is lab services

Laboratory Products and Biopharma Services54%modest
Life Sciences Solutions20%modest
Analytical Instruments15%flat
Specialty Diagnostics11%flat

Segment mix uses external customer revenue from 2026 filings. End-market trends can differ from segment trends because each segment sells into several customer groups.

05 Risk factors

What could break the case

Academic and government budgets stall

Medium impact · High odds

While China and pharma markets have accelerated, academic and government spending remains flat globally. These customers often buy instruments with budget money. If budgets stay tight, the overall recovery could stall.

We watchWatch for management comments on global academic and government funding in each earnings call.

Organic growth stays modest

High impact · Medium odds

The company maintained its 2026 guidance, expecting full-year organic growth of about 4 percent. Management noted that some third-quarter strength was pulled forward. If growth does not sustainably accelerate past this range, the market may question the long-term growth story.

We watchWatch quarterly organic revenue growth and whether management can sustain or beat the 4 percent level.

Cybersecurity and AI-related attacks

High impact · Medium odds

The company added specific language about cyber attacks becoming more sophisticated, especially with artificial intelligence. Thermo Fisher handles sensitive research, clinical, and customer data. A major breach could hurt trust, operations, and costs.

We watchWatch for disclosed cyber incidents, higher security spending, or new risk language in filings.

Talent shortages in advanced science

Medium impact · Medium odds

Thermo Fisher says its success depends on attracting and keeping highly qualified scientific, technical, clinical, and management talent. Demand for artificial intelligence and other advanced skills makes that harder. If it cannot hire or retain key people, product development could suffer.

We watchWatch hiring commentary, restructuring updates, and any signs of slower product launches or service issues.
06 Quick answers

In one breath

What does Thermo Fisher Scientific actually do?

Thermo Fisher sells the tools, supplies, tests, and services that labs and drug companies use. Its products help customers do research, run diagnostics, manage clinical trials, and make biologic drugs.

Why is pharma and biotech so important for Thermo Fisher?

Pharma and biotech customers buy across many Thermo Fisher businesses, from bioproduction supplies to clinical research services. In the third quarter of 2026, that end market delivered high single-digit growth.

Is Thermo Fisher growing fast right now?

Growth is improving. The third quarter of 2026 saw 6 percent organic growth, though management noted some of this was a timing pull-forward. Full-year guidance remains at about 4 percent.

What is the biggest thing to watch next?

Watch whether organic growth can sustainably push past 4 percent. Also watch whether academic and government spending globally finally recovers from its flat trend.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
October 25, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Thermo Fisher Scientific Q3 2026 Earnings Transcript
  2. Thermo Fisher Scientific Q2 2026 Form 10-Q
08 Explore the industry

Comparable Diagnostics & Research companies

Companies near Thermo Fisher Scientific Inc. in Finn's Diagnostics & Research industry ranking.

Get started with Finn today